US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Super League Gaming Inc.

5.53

-0.1150-2.04%

Pre-market: 5.550.0250+0.45%04:00 EDT

Volume:140.46K

Turnover:776.01K

Market Cap:13.66M

PE:-0.45

High:5.79

Open:5.61

Low:5.28

Close:5.64

52wk High:61.44

52wk Low:2.12

Shares:2.47M

Float Shares:2.02M

Volume Ratio:0.71

T/O Rate:6.95%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-12.3857

EPS(LYR):-40.4307

ROE:-503.98%

ROA:-64.67%

PB:1.06

PE(LYR):-0.14

Loading ...

Overview Company News Filings

Super League Enterprise director Robert Kalutkiewicz files initial beneficial ownership statement

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Super League names Robert Kalutkiewicz to board as Mark Jung steps down

Super League closes acquisition of Misfits Ads Division from Misfits Gaming Group

LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis

Super League sets first-quarter 2026 earnings release, hosts results webinar

Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results

INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

Cabaletta Bio reports promising RESET-PV and RESET-SLE data

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE

InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability

Press Release: Super League Issues Letter Encouraging Shareholders to Vote in Support of the Misfits Ads Division Acquisition

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/SLE/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":5.525,"timestamp":1790798400000,"preClose":5.64,"halted":0,"volume":140460,"hourTrading":{"tag":"盘前","latestPrice":5.55,"preClose":5.525,"latestTime":"04:00 EDT","volume":104,"amount":577.1999999999999,"timestamp":1790841608401,"change":0.025,"changeRate":0.004525,"amplitude":0},"delay":0,"changeRate":-0.020390070921985696,"floatShares":2020495,"shares":2473200,"eps":-12.385672,"marketStatus":"Pre-Mkt","change":-0.115,"latestTime":"10-01 06:29:06 EDT","open":5.61,"high":5.788,"low":5.28,"amount":776005.82316,"amplitude":0.090071,"askPrice":5.85,"askSize":50,"bidPrice":4.71,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-12.385672,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790861400000},"marketStatusCode":1,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":5.525,"preHourTrading":{"tag":"盘前","latestPrice":5.55,"preClose":5.525,"latestTime":"04:00 EDT","volume":104,"amount":577.1999999999999,"timestamp":1790841608401,"change":0.025,"changeRate":0.004525,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":5.55,"preClose":5.525,"latestTime":"19:30 EDT","volume":1219,"amount":6676.5544,"timestamp":1790811001931,"change":0.025,"changeRate":0.004525,"amplitude":0.034389},"volumeRatio":0.7097093653125519},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":2020495,"roa":"-64.67%","roe":"-503.98%","lyrEps":-40.430703,"volumeRatio":0.7097093653125519,"shares":2473200,"dividePrice":0,"high":5.788,"amplitude":0.090071,"preClose":5.64,"low":5.28,"week52Low":2.12,"pbRate":"1.06","psRate":"1.17","week52High":61.44,"institutionHeld":0,"latestPrice":5.525,"committee":0.333333,"eps":-12.385672,"divideRate":0,"volume":140460,"delay":0,"ttmEps":-12.385672,"open":5.61,"prevYearClose":7.326,"prevWeekClose":5.03,"prevMonthClose":5.525,"prevQuarterClose":5.525,"fiveDayClose":5.26,"twentyDayClose":3.73,"sixtyDayClose":2.93},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"SLE","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-2.7},{"market":"US","date":"2026-05-15","symbol":"SLE","fiscalQuarterEnding":"2026/03","expectedEps":-2.64,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-1.77},{"market":"US","date":"2026-03-27","symbol":"SLE","fiscalQuarterEnding":"2025/12","expectedEps":-3.12,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774584000000,"reportTimeType":"pre","actualEps":-9.44},{"market":"US","date":"2026-01-23","symbol":"SLE","defaultRemindTime":1769178600000,"type":"split","dateTimestamp":1769144400000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2025-11-13","symbol":"SLE","fiscalQuarterEnding":"2025/09","expectedEps":-2.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-2.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1782792000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2026-09-29","current":-0.44608,"percent":0.212737,"low":-0.738945,"twenty":-0.349642,"median":-0.269443,"eighty":-0.213599,"high":-0.044016,"avg":-0.283143,"sd":0.114905,"marketCap":7644991},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557},{"date":"2025-04-04","current":-0.234475,"twenty":-0.342935,"median":-0.283459,"eighty":-0.210567,"marketCap":3900496},{"date":"2025-04-11","current":-0.236161,"twenty":-0.340036,"median":-0.28231,"eighty":-0.212359,"marketCap":3928533},{"date":"2025-04-17","current":-0.236161,"twenty":-0.338893,"median":-0.280718,"eighty":-0.213857,"marketCap":3928533},{"date":"2025-04-25","current":-0.369736,"twenty":-0.338893,"median":-0.280836,"eighty":-0.213857,"marketCap":6150554},{"date":"2025-05-02","current":-0.394848,"twenty":-0.347107,"median":-0.282596,"eighty":-0.213857,"marketCap":6568294},{"date":"2025-05-09","current":-0.347723,"twenty":-0.34901,"median":-0.284084,"eighty":-0.213899,"marketCap":5784365},{"date":"2025-05-16","current":-0.174182,"twenty":-0.348716,"median":-0.282596,"eighty":-0.211859,"marketCap":2897515},{"date":"2025-05-23","current":-0.187657,"twenty":-0.347631,"median":-0.280836,"eighty":-0.209762,"marketCap":2928392},{"date":"2025-05-30","current":-0.243307,"twenty":-0.347723,"median":-0.280836,"eighty":-0.209995,"marketCap":3796802},{"date":"2025-06-06","current":-0.252949,"twenty":-0.347265,"median":-0.280718,"eighty":-0.210038,"marketCap":3947265},{"date":"2025-06-13","current":-0.226363,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"marketCap":3532387},{"date":"2025-06-20","current":-0.204904,"twenty":-0.346791,"median":-0.280097,"eighty":-0.210029,"marketCap":3197521},{"date":"2025-06-27","current":-0.222294,"twenty":-0.344958,"median":-0.279367,"eighty":-0.209283,"marketCap":3468896},{"date":"2025-07-03","current":-0.240225,"twenty":-0.342139,"median":-0.277573,"eighty":-0.209588,"marketCap":3748716},{"date":"2025-07-11","current":-0.314762,"twenty":-0.339781,"median":-0.277296,"eighty":-0.209879,"marketCap":4911855},{"date":"2025-07-18","current":-0.242124,"twenty":-0.33814,"median":-0.276346,"eighty":-0.210021,"marketCap":3778350},{"date":"2025-07-25","current":-0.228831,"twenty":-0.337327,"median":-0.276269,"eighty":-0.210038,"marketCap":3570911},{"date":"2025-08-01","current":-0.243781,"twenty":-0.33696,"median":-0.274358,"eighty":-0.210831,"marketCap":3804205},{"date":"2025-08-08","current":-0.233576,"twenty":-0.336712,"median":-0.273838,"eighty":-0.212858,"marketCap":3644959},{"date":"2025-08-15","current":-0.231876,"twenty":-0.33606,"median":-0.271353,"eighty":-0.213354,"marketCap":3618418},{"date":"2025-08-22","current":-0.221928,"twenty":-0.335323,"median":-0.269787,"eighty":-0.212104,"marketCap":3535981},{"date":"2025-08-29","current":-0.23749,"twenty":-0.333566,"median":-0.269388,"eighty":-0.213354,"marketCap":3783930},{"date":"2025-09-05","current":-0.192157,"twenty":-0.332345,"median":-0.269014,"eighty":-0.213084,"marketCap":3061642},{"date":"2025-09-12","current":-0.207719,"twenty":-0.332042,"median":-0.268116,"eighty":-0.210012,"marketCap":3309592},{"date":"2025-09-19","current":-0.247639,"twenty":-0.331721,"median":-0.267958,"eighty":-0.20982,"marketCap":3945637},{"date":"2025-09-26","current":-0.362878,"twenty":-0.332345,"median":-0.267958,"eighty":-0.210012,"marketCap":5781732},{"date":"2025-10-03","current":-0.272683,"twenty":-0.334082,"median":-0.268394,"eighty":-0.210038,"marketCap":4344654},{"date":"2025-10-10","current":-0.24891,"twenty":-0.332345,"median":-0.268116,"eighty":-0.210567,"marketCap":3965889},{"date":"2025-10-17","current":-0.321134,"twenty":-0.33627,"median":-0.269014,"eighty":-0.211856,"marketCap":5116629},{"date":"2025-10-24","current":-0.188157,"twenty":-0.335429,"median":-0.268704,"eighty":-0.211856,"marketCap":2997912},{"date":"2025-10-31","current":-0.131167,"twenty":-0.334082,"median":-0.267958,"eighty":-0.20982,"marketCap":2089890},{"date":"2025-11-07","current":-0.105839,"twenty":-0.332345,"median":-0.267719,"eighty":-0.208727,"marketCap":1686325},{"date":"2025-11-14","current":-0.110362,"twenty":-0.332042,"median":-0.267321,"eighty":-0.207583,"marketCap":1758390},{"date":"2025-11-21","current":-0.081028,"twenty":-0.331721,"median":-0.26512,"eighty":-0.206427,"marketCap":1285354},{"date":"2025-11-28","current":-0.659255,"twenty":-0.334597,"median":-0.266863,"eighty":-0.206708,"marketCap":10457765},{"date":"2025-12-05","current":-0.720254,"twenty":-0.337177,"median":-0.26748,"eighty":-0.207472,"marketCap":11425396},{"date":"2025-12-12","current":-0.614194,"twenty":-0.34219,"median":-0.267958,"eighty":-0.207492,"marketCap":9742959},{"date":"2025-12-19","current":-0.474574,"twenty":-0.347254,"median":-0.268394,"eighty":-0.207537,"marketCap":7528174},{"date":"2025-12-26","current":-0.4608,"twenty":-0.349022,"median":-0.269014,"eighty":-0.207719,"marketCap":7309663},{"date":"2026-01-02","current":-0.447318,"twenty":-0.351152,"median":-0.26966,"eighty":-0.207719,"marketCap":7095801},{"date":"2026-01-09","current":-0.503223,"twenty":-0.354793,"median":-0.269873,"eighty":-0.208261,"marketCap":7982631},{"date":"2026-01-16","current":-0.526743,"twenty":-0.360917,"median":-0.271353,"eighty":-0.208641,"marketCap":8355727},{"date":"2026-01-23","current":-0.388481,"twenty":-0.368101,"median":-0.272683,"eighty":-0.20874,"marketCap":6162476},{"date":"2026-01-30","current":-0.377954,"twenty":-0.369864,"median":-0.273838,"eighty":-0.208765,"marketCap":5995491},{"date":"2026-02-06","current":-0.254616,"twenty":-0.369341,"median":-0.274166,"eighty":-0.209154,"marketCap":4038966},{"date":"2026-02-13","current":-0.250952,"twenty":-0.368944,"median":-0.274262,"eighty":-0.209588,"marketCap":3980851},{"date":"2026-02-20","current":-0.244846,"twenty":-0.368353,"median":-0.273838,"eighty":-0.20982,"marketCap":3883993},{"date":"2026-02-27","current":-0.219812,"twenty":-0.367557,"median":-0.272683,"eighty":-0.209529,"marketCap":3486877},{"date":"2026-03-06","current":-0.285756,"twenty":-0.365648,"median":-0.271783,"eighty":-0.20982,"marketCap":4532940},{"date":"2026-03-13","current":-0.266522,"twenty":-0.361898,"median":-0.272212,"eighty":-0.210012,"marketCap":4227838},{"date":"2026-03-20","current":-0.285756,"twenty":-0.360355,"median":-0.272267,"eighty":-0.210038,"marketCap":4532940},{"date":"2026-03-27","current":-0.254616,"twenty":-0.358486,"median":-0.271712,"eighty":-0.210567,"marketCap":4038966},{"date":"2026-04-02","current":-0.208821,"twenty":-0.355643,"median":-0.27114,"eighty":-0.210302,"marketCap":3312533},{"date":"2026-04-10","current":-0.260127,"twenty":-0.354839,"median":-0.269787,"eighty":-0.210302,"marketCap":5389056},{"date":"2026-04-17","current":-0.281981,"twenty":-0.354827,"median":-0.26986,"eighty":-0.211608,"marketCap":5841796},{"date":"2026-04-24","current":-0.268594,"twenty":-0.354771,"median":-0.270513,"eighty":-0.212842,"marketCap":5564456},{"date":"2026-05-01","current":-0.267882,"twenty":-0.354343,"median":-0.269886,"eighty":-0.213819,"marketCap":5549706},{"date":"2026-05-08","current":-0.295375,"twenty":-0.352599,"median":-0.271247,"eighty":-0.213857,"marketCap":6119281},{"date":"2026-05-15","current":-0.286915,"twenty":-0.351648,"median":-0.272111,"eighty":-0.213857,"marketCap":5944027},{"date":"2026-05-22","current":-0.634562,"twenty":-0.354827,"median":-0.272503,"eighty":-0.213857,"marketCap":13032642},{"date":"2026-05-29","current":-0.249501,"twenty":-0.354781,"median":-0.272503,"eighty":-0.213857,"marketCap":5124247},{"date":"2026-06-05","current":-0.248769,"twenty":-0.35473,"median":-0.272212,"eighty":-0.214067,"marketCap":5109220},{"date":"2026-06-12","current":-0.241452,"twenty":-0.352795,"median":-0.271911,"eighty":-0.214067,"marketCap":4958949},{"date":"2026-06-18","current":-0.230477,"twenty":-0.35201,"median":-0.271247,"eighty":-0.214405,"marketCap":4733542},{"date":"2026-06-26","current":-0.225356,"twenty":-0.351152,"median":-0.269886,"eighty":-0.214489,"marketCap":4628352},{"date":"2026-07-02","current":-0.229746,"twenty":-0.35011,"median":-0.269715,"eighty":-0.214549,"marketCap":4718515},{"date":"2026-07-10","current":-0.220234,"twenty":-0.349224,"median":-0.269201,"eighty":-0.214489,"marketCap":4523163},{"date":"2026-07-17","current":-0.207795,"twenty":-0.349022,"median":-0.268594,"eighty":-0.214067,"marketCap":4267702},{"date":"2026-07-24","current":-0.19682,"twenty":-0.348987,"median":-0.268161,"eighty":-0.213857,"marketCap":4042295},{"date":"2026-07-31","current":-0.20121,"twenty":-0.348468,"median":-0.267958,"eighty":-0.213493,"marketCap":4132458},{"date":"2026-08-07","current":-0.202674,"twenty":-0.34754,"median":-0.267882,"eighty":-0.210977,"marketCap":4162512},{"date":"2026-08-14","current":-0.245842,"twenty":-0.347244,"median":-0.2674,"eighty":-0.211398,"marketCap":5049112},{"date":"2026-08-21","current":-0.293824,"twenty":-0.347244,"median":-0.26748,"eighty":-0.210977,"marketCap":6506742},{"date":"2026-08-28","current":-0.291642,"twenty":-0.347002,"median":-0.26792,"eighty":-0.211398,"marketCap":6458407},{"date":"2026-09-04","current":-0.269443,"twenty":-0.345822,"median":-0.267958,"eighty":-0.211454,"marketCap":5966822},{"date":"2026-09-11","current":-0.349817,"twenty":-0.347254,"median":-0.268274,"eighty":-0.211683,"marketCap":7746698},{"date":"2026-09-18","current":-0.352113,"twenty":-0.348716,"median":-0.268804,"eighty":-0.212737,"marketCap":7797552},{"date":"2026-09-25","current":-0.410289,"twenty":-0.349431,"median":-0.269388,"eighty":-0.213388,"marketCap":9085843},{"date":"2026-09-29","current":-0.345224,"twenty":-0.349642,"median":-0.269443,"eighty":-0.213599,"marketCap":7644991}],"updateTime":1790816652972},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633732453","title":"Super League Enterprise director Robert Kalutkiewicz files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2633732453","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633732453?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:43","pubTimestamp":1778240620,"startTime":"0","endTime":"0","summary":"Super League Enterprise filed an initial beneficial ownership statement naming Robert Kalutkiewicz as a director, dated May 6.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Super League Enterprise Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL9ZBzpw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633453731","title":"Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633453731","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633453731?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ER","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289829/0/en/Climb-Bio-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","BK4181","SLE","ITP","BK4077","BK4218","BK4023","PK","PD","BK4199","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145383","title":"Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145383","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145383?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 Zipalertinib NDA for relap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289800/0/en/Cullinan-Therapeutics-Provides-Corporate-Update-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","BK4139","CGEM","SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633113571","title":"Super League names Robert Kalutkiewicz to board as Mark Jung steps down","url":"https://stock-news.laohu8.com/highlight/detail?id=2633113571","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633113571?lang=en_us&edition=fundamental","pubTime":"2026-05-06 21:02","pubTimestamp":1778072538,"startTime":"0","endTime":"0","summary":"Super League named Robert Kalutkiewicz to board, effective today, as condition of closing acquisition of Misfits Ads Division.Kalutkiewicz serves as senior vice president of corporate development, strategy, strategic investments at E.W. Scripps.Justin Stefanovic joined management as senior vice president of business development and platform strategy, coming from senior vice president role at Misfits Gaming Group.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Super League Enterprise Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the inform","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL8FcbLN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","BK4125","SSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633135089","title":"Super League closes acquisition of Misfits Ads Division from Misfits Gaming Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2633135089","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633135089?lang=en_us&edition=fundamental","pubTime":"2026-05-06 21:02","pubTimestamp":1778072527,"startTime":"0","endTime":"0","summary":"Super League closed its acquisition of Misfits Gaming Group’s Misfits Ads Division, adding a programmatic advertising business and proprietary rewarded-video monetization technology.Contribution to financial results expected to begin in Q2, supporting a target of cash-based EBITDA profitability by year end.Deal expands scale in gaming advertising, targeting an under-monetized market where US gaming ad spend is near $10 billion versus more than $150 billion across social and streaming.Transaction includes a preferred commercial brand partnership with Misfits Gaming Group covering brand integrations across Roblox games reaching more than 100 million monthly active users.Board changes tied to closing include Robert Kalutkiewicz joining as a director, replacing Mark Jung; former Misfits executive Justin Stefanovic joined as SVP of business development and platform strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL3Fm7Lt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4535","LU2264538146.SGD","RBLY","IE0001KFT4U8.USD","RBLU","LU1861559042.SGD","BK4565","LU1861558580.USD","RBLX","LU1064131342.USD","BK4588","BK4551","LU0786609619.USD","BK4547","LU2543165471.USD","BK4085","BK4554","SLE","BK4585","LU0348723411.USD","LU1988902786.USD","BK4598"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633972146","title":"LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2633972146","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633972146?lang=en_us&edition=fundamental","pubTime":"2026-05-06 10:57","pubTimestamp":1778036220,"startTime":"0","endTime":"0","summary":"NANJING, China, May  05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (\"Leads Biolabs\"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASD","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288455/0/en/LBL-047-Prioritized-for-Clinical-Development-in-Sj%C3%B6gren-s-Disease-Systemic-Lupus-Erythematosus-and-Dermatomyositis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4546","SLE","DM","DNTH","BK4139","BK4161","TACI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633146924","title":"Super League sets first-quarter 2026 earnings release, hosts results webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2633146924","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633146924?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:45","pubTimestamp":1778013905,"startTime":"0","endTime":"0","summary":"Super League to release first-quarter 2026 results before market open May 15, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL7GSTxT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014039.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","BK4112","IE00B3QW5Z07.USD","SLE","IE00B64PRP62.GBP","SG9999014021.USD","BK4077","NDAQ","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4588","BK4585","LU0314104364.USD","SG9999014013.SGD","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014005.SGD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633251929","title":"Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633251929","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633251929?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:01","pubTimestamp":1778011260,"startTime":"0","endTime":"0","summary":"Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A. Claseprubart granted Orphan Drug Designation by FDA for Myasthenia Gravis. Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis  on track to initiate in mid-2026; top-line results anticipated in 2H'28. Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy  ongoing; top-line results on track for Q4'26. Building a rheumatology franchise around DNTH212 with first three priority indications of Sjgren's Disease , Systemic Lupus Erythematosus , and Dermatomyositis . Further strengthened the balance sheet with approximately $719 million in gross proceeds from an underwritten public offering of common stock and pre-funded warrants. Approximately $1.2 billion of cash as of March 31, 2026 provides expected runway into 2030. NEW YORK and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4178","BK4139","DM","BK4546","BK4007","SLE","DNTH","BK4161","BK4539","AAN","LENZ","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633254209","title":"INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2633254209","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633254209?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:00","pubTimestamp":1778011200,"startTime":"0","endTime":"0","summary":"LONDON, UK and BOCA RATON, FL, May  05, 2026 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (“INmune Bio”), a clinical-stage biotechnology company, and Anthony Nolan, a pioneering UK-based charit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3288193/0/en/INmune-Bio-and-Anthony-Nolan-Announce-Strategic-Expansion-of-CORDStrom-MSC-Platform-Collaboration-to-Target-RDEB-Oncology-and-Inflammatory-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4139","BK4150","BK4575","MSC","BK4077","INMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633425948","title":"Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819","url":"https://stock-news.laohu8.com/highlight/detail?id=2633425948","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633425948?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:30","pubTimestamp":1777984200,"startTime":"0","endTime":"0","summary":"FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287697/24675/en/Fate-Therapeutics-Selected-for-U-S-FDA-Chemistry-Manufacturing-and-Controls-Development-and-Readiness-Pilot-Program-to-Support-Manufacturing-Readiness-of-FT819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1363072403.SGD","LU0267386448.USD","LU0170899867.USD","LU2746668461.USD","IE00BKVL7J92.USD","LU0971096721.USD","LU0882574139.USD","IE00BZ1G4Q59.USD","LU2746668974.SGD","BK4230","LU2237443978.SGD","BK4588","LU2237443382.USD","LU2237443622.USD","BK4585","LU2237443549.SGD","IE00B1BXHZ80.USD","LU2237443465.HKD","BK4006","CAR","BK4022","BK4077","CMC","LABU","LU2237443895.HKD","IE00BHPRN162.USD","BK4139","SLE","FATE","IE00BFXG1179.USD","LU0149725797.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633914063","title":"Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2633914063","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633914063?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:00","pubTimestamp":1777978800,"startTime":"0","endTime":"0","summary":"Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; Fast T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287504/0/en/Climb-Bio-Hosts-Budoprutug-R-D-Spotlight-Event-Highlighting-Topline-Subcutaneous-Formulation-Data-Broad-B-Cell-Mediated-Disease-Opportunity-and-Upcoming-Data-Readouts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","ITP","BK4199","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633969366","title":"CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633969366","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633969366?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:30","pubTimestamp":1777926600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, May  04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first quarter reflec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3287176/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","LU1720051017.SGD","LU2543165471.USD","BK4139","KSA","LU1064131342.USD","LU0868494617.USD","BK4611","LU2023250504.SGD","BK4504","BK4556","LU1988902786.USD","BK4597","LU1548497426.USD","LU0742534661.SGD","BK4585","AGT","CAT","LU0048573561.USD","SCD","LU0868494708.USD","BK4516","BK4077","LU1861558580.USD","CRSP","LU2106854487.HKD","LU1974910355.USD","BK4149","SLE","BK4199","CAR","LU1917777945.USD","LU1720051108.HKD","LU2264538146.SGD","BK4022","LU2237438978.USD","BK4520","LU0251142724.SGD","IE00BD6J9T35.USD","IE00BSNM7G36.USD","LU2357305700.SGD","LU1861559042.SGD","FXI","UAE","LU0963586101.USD","ITP","LU0251131958.USD","LU0942090050.USD","BK4532","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632554409","title":"Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2632554409","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632554409?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3286762/24675/en/Fate-Therapeutics-Announces-Three-Presentations-at-the-2026-ASGCT-Annual-Meeting-Highlighting-Off-the-Shelf-CAR-T-cell-Therapy-Pipeline-for-Cancer-and-Autoimmune-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4022","BK4139","CAR","BK4077","FATE","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632324929","title":"Cabaletta Bio reports promising RESET-PV and RESET-SLE data","url":"https://stock-news.laohu8.com/highlight/detail?id=2632324929","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632324929?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:32","pubTimestamp":1777890762,"startTime":"0","endTime":"0","summary":"Cabaletta Bio ( ($CABA) ) has issued an update. On May 14, 2026, Cabaletta Bio planned to present new clinical and translational data from four ref...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cabaletta-bio-reports-promising-reset-pv-and-reset-sle-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cabaletta-bio-reports-promising-reset-pv-and-reset-sle-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CABA","SLE","BK4077","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631630119","title":"Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631630119","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631630119?lang=en_us&edition=fundamental","pubTime":"2026-04-30 21:00","pubTimestamp":1777554000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284910/24675/en/Fate-Therapeutics-Announces-Data-Presentation-of-FT819-Off-the-Shelf-CAR-T-Cell-Product-Candidate-for-Systemic-Lupus-Erythematosus-SLE-at-the-CCR-East-2026-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","CAR","BK4077","BK4139","BK4230","SLE","FATE","CCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631512824","title":"XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2631512824","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631512824?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:58","pubTimestamp":1777467480,"startTime":"0","endTime":"0","summary":"Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum Seven Approved Phase 2a Human Clinical Trials Expect","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3283784/0/en/XTL-Biopharmaceuticals-to-Acquire-Psyga-Bio-Establishing-a-Leading-Psychedelic-Biotechnology-Platform-with-Advanced-Clinical-Pipeline-Licensed-GMP-Manufacturing-and-Proprietary-Psi.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEIS","XTL","LU0757428866.USD","XTLB","IE0031619046.USD","IE00B19Z4B17.USD","BK4157","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4139","SLE","LU1815336091.USD","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631116555","title":"InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE","url":"https://stock-news.laohu8.com/highlight/detail?id=2631116555","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631116555?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:37","pubTimestamp":1777423020,"startTime":"0","endTime":"0","summary":"BEIJING, April  28, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3283360/0/en/InnoCare-Announces-First-Patient-Dosed-in-Phase-III-Trial-of-Orelabrutinib-for-SLE.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","SLE","BK4077","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629837806","title":"InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2629837806","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629837806?lang=en_us&edition=fundamental","pubTime":"2026-04-23 21:20","pubTimestamp":1776950400,"startTime":"0","endTime":"0","summary":"BEIJING, April  23, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced its results and business highlights for the first quarter of 2026 as of 31 March 2026. Over the ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/23/3280053/0/en/InnoCare-Releases-2026-Q1-Results-Strong-Revenue-Growth-and-Sustained-Profitability.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0912757837.SGD","LU2271345857.HKD","BK4588","LU0006306889.USD","LU0158827948.USD","BK4581","LU1720051017.SGD","LU0106831901.USD","LU0795875086.SGD","LU0320765646.SGD","LU2089283258.USD","LU0557290698.USD","LU0106261372.USD","LU0528227936.USD","LU2028103732.USD","LU1732800096.USD","LU2089284900.SGD","LU0314104364.USD","BK4585","LU1244550494.USD","BK4132","ITP","SLE","AD","LU1732799900.SGD","LU0971096721.USD","LU1989772923.USD","IBD","LU1244550221.USD","BK4534","BK4516","IE00BKVL7J92.USD","BK4077","LU2347655156.SGD","BK4199","LU0882574139.USD","LU1162221912.USD","BK4504","LU0158827781.USD","LU2111349929.HKD","LU0225283273.USD","LU2023251221.USD","LU2133065610.SGD","LU2357305700.SGD","LU1244550577.SGD","BK4127","LU0234570918.USD","LU0795875169.SGD","LU1074936037.SGD","LU1791710400.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628725523","title":"Press Release: Super League Issues Letter Encouraging Shareholders to Vote in Support of the Misfits Ads Division Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2628725523","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628725523?lang=en_us&edition=fundamental","pubTime":"2026-04-20 21:01","pubTimestamp":1776690060,"startTime":"0","endTime":"0","summary":"Transaction will add pro-forma profitable revenue, enhance predictability of financial performance, expand market share, and accelerate the Company's path to sustainable cash-based EBITDA profitability. Management encourages Shareholders to vote in favor of the proposal.SANTA MONICA, Calif., April 20, 2026  -- Super League  , an audience intelligence and media activation company trusted by global brands to reach and influence people who play video games across the digital landscape, issued a letter to shareholders from the Company's Chairman and Chief Executive Officer, Matt Edelman.We recently announced our agreement to acquire the Misfits Ads Division. Already generating profitable revenue, integrating the division is fully expected to improve the predictability of our performance, expand our market share, and accelerate our path to cash-based EBITDA profitability. We believe it is an important step and ideal opportunity for Super League to build sustainable operating momentum and sh","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627842912","title":"Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2627842912","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627842912?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:30","pubTimestamp":1776256200,"startTime":"0","endTime":"0","summary":"Study Highlights Dagger Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and Persistence of Allogeneic CAR T Cells in Pre-","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/15/3274436/0/en/Allogene-Therapeutics-Announces-Nature-Communications-Publication-Highlighting-Pre-Clinical-Data-for-ALLO-329-a-Next-Generation-Dual-Targeted-CD19-CD70-Allogeneic-CAR-T-for-Autoimm.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4230","BK4077","CAR","ALLO","BK4139","BK4022","SLE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":102,"code":"91000000","status":"200"}]}}